Kailera Therapeutics, Inc.Kailera Therapeutics, Inc.
KLRAKailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.
Market cap
$1.3BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Kailera Therapeutics has exceptional short-term liquidity from very high current assets versus liabilities. Growth and profitability trends cannot be identified due to missing quarterly metrics, and all return measures are negative.
As of 2026-06-30Market
Listed stock
KLRAPriceNasdaqLoading…Loading…1Y